Alerts will be sent to your verified email
Verify EmailHIKAL
Hikal
|
Neuland Laboratories
|
PI Industries
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
4.0 % | 2.53 % | n/a |
Financials
|
|||
5 yr Average ROE
|
12.04 % | 7.78 % | 16.01 % |
5yr average Equity Multiplier
|
2.23 | 1.65 | 1.59 |
5yr Average Asset Turnover Ratio
|
0.84 | 0.67 | 0.64 |
5yr Avg Net Profit Margin
|
6.39 % | 6.73 % | 15.8 % |
Price to Book
|
3.5 | 7.65 | 6.6 |
P/E
|
59.7 | 32.69 | 34.27 |
5yr Avg Cash Conversion Cycle
|
44.89 Days | 64.68 Days | 30.17 Days |
Inventory Days
|
66.84 Days | 94.42 Days | 71.45 Days |
Days Receivable
|
79.34 Days | 91.33 Days | 44.38 Days |
Days Payable
|
84.24 Days | 114.5 Days | 101.84 Days |
5yr Average Interest Coverage Ratio
|
4.97 | 7.45 | 48.31 |
5yr Avg ROCE
|
15.64 % | 11.07 % | 18.47 % |
5yr Avg Operating Profit Margin
|
17.42 % | 15.88 % | 24.01 % |
5 yr average Debt to Equity
|
0.72 | 0.26 | 0.06 |
5yr CAGR Net Profit
|
-5.33 % | 58.32 % | 24.55 % |
5yr Average Return on Assets
|
5.39 % | 4.76 % | 10.13 % |
Shareholdings
|
|||
Promoter Holding
|
68.85 % | 32.74 % | 46.09 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.08 % | -3.48 % | -0.65 % |
Change in Mutual Fund Holding (3 Yrs)
|
2.58 % | 3.01 % | 1.13 % |
Hikal
|
Neuland Laboratories
|
PI Industries
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
Operating Profit Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|